title: Reverse cascade screening of newborns for hereditary haemochromatosis: a model for other late onset diseases?
abstract: BACKGROUND
  Genetic testing can determine those at risk for hereditary haemochromatosis (HH) caused by HFE mutations before the onset of symptoms. However, there is no optimum screening strategy, mainly owing to the variable penetrance in those who are homozygous for the HFE Cys282Tyr (C282Y) mutation. The objective of this study was to identify the majority of individuals at serious risk of developing HFE haemochromatosis before they developed life threatening complications.
  
  
  METHODS
  We first estimated the therapeutic penetrance of the C282Y mutation in people living in la Somme, France, using genetic, demographic, biochemical, and follow up data. We examined the benefits of neonatal screening on the basis of increased risk to relatives of newborns carrying one or two copies of the C282Y mutation. Between 1999 and 2002, we screened 7038 newborns from two maternity hospitals in the north of France for the C282Y and His63Asp (H63D) mutations in the HFE gene, using bloodspots collected on Guthrie cards. Family studies and genetic counselling were undertaken, based on the results of the baby's genotype.
  
  
  RESULTS
  In la Somme, we found that 24% of the adults homozygous for the C282Y mutation required at least 5 g iron to be removed to restore normal iron parameters (that is, the therapeutic penetrance). In the reverse cascade screening study, we identified 19 C282Y homozygotes (1/370), 491 heterozygotes (1/14) and 166 compound heterozygotes (1/42) in 7038 newborns tested. The reverse cascade screening strategy resulted in 80 adults being screened for both mutations. We identified 10 previously unknown C282Y homozygotes of whom six (four men and two women) required venesection. Acceptance of neonatal screening was high; parents understood the risks of having HH and the benefits of early detection, but a number of parents were reluctant to take the test themselves. Neonatal screening for HH is straightforward. Reverse cascade screening increased the efficiency of detecting affected adults with undiagnosed haemochromatosis. This strategy allows almost complete coverage for HH and could be a model for efficient screening for other late onset genetic diseases.
authors.affiliation: Department of Medical Genetics and UMR-INERIS, Centre Hospitalo-Universitaire et Faculté de Médecine, 3 rue des Louvels, 80036, Amiens, France.
authors.forename: E
authors.initials: E
authors.lastname: Cadet
authors.forename: D
authors.initials: D
authors.lastname: Capron
authors.forename: M
authors.initials: M
authors.lastname: Gallet
authors.forename: M-L
authors.initials: ML
authors.lastname: Omanga-Léké
authors.forename: H
authors.initials: H
authors.lastname: Boutignon
authors.forename: C
authors.initials: C
authors.lastname: Julier
authors.forename: K J H
authors.initials: KJ
authors.lastname: Robson
authors.forename: J
authors.initials: J
authors.lastname: Rochette
mesh_terms: D000328:Adult; D017668:Age of Onset; D002648:Child; D005260:Female; D006580:Genetic Carrier Screening; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing / Q000379:methods*; D006432:Hemochromatosis / Q000175:diagnosis* / Q000453:epidemiology / Q000235:genetics; D000071020:Hemochromatosis Protein; D006579:Heterozygote; D015395:Histocompatibility Antigens Class I / Q000235:genetics*; D006720:Homozygote; D006801:Humans; D007231:Infant, Newborn; D007501:Iron / Q000097:blood; D008297:Male; D008565:Membrane Proteins / Q000235:genetics*; D008875:Middle Aged; D015997:Neonatal Screening / Q000379:methods*
chemical_list: C103673:HFE protein, human; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I; D008565:Membrane Proteins; D007501:Iron